Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback